Vergoeding 2018-2022 voor ATC-subgroep V03AE : Middelen bij hyperkaliemie en hyperfosfatemie
- Raming voor de totale Zvw-populatie
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| V03AE01 Polystyreensulfonzuur (na-zout ca-zout) (Resonium a ®) | 1.689.400 | 1.639.500 | 1.591.400 | 1.555.100 | 1.458.400 |
| V03AE02 Sevelameer (Renagel ®) | 3.692.500 | 2.956.700 | 2.793.400 | 2.366.000 | 2.362.400 |
| V03AE03 Lanthaancarbonaat (Fosrenol ®) | 3.270.000 | 3.653.400 | 3.673.900 | 3.467.800 | 3.474.900 |
| V03AE04 Calciumacetaat met magnesiumcarbonaat (Osvaren ®) | 58.631 | 77.003 | 80.856 | 77.873 | 78.063 |
| V03AE05 Ferrioxyhydroxide-sucrose-complex (Velphoro ®) | 564.900 | 591.810 | 574.380 | 562.420 | 533.200 |
| V03AE07 Calciumacetaat | . | 279 | 3.988 | 4.818 | 4.386 |
| V03AE09 Patiromeer calcium (Veltassa ®) | . | 15.752 | 114.130 | 229.970 | 348.090 |
| V03AE10 Natriumzirconiumcyclosilicaat (Lokelma ®) | . | . | . | 102.990 | 301.170 |
| Totaal | 9.275.431 | 8.934.444 | 8.832.054 | 8.366.971 | 8.560.609 |